Charles Link

Dr. Link grew up in Bellaire, Ohio, and after attending the U.S. Air Force Academy, earned his medical degree with honors from Stanford. He completed his residency at UCSF and an oncology fellowship at the National Cancer Institute, later serving as Director of the Stoddard Cancer Research Institute.
He currently serves as Founder, Executive Chairman and Chief Innovation Officer of Syncromune, driving its breakthrough SYNC-T Therapy platform, and as an Adjunct Professor at the Lankenau Institute for Medical Research. An expert in translational research, he previously founded NewLink Genetics to leverage the immune system against cancer and founded BioProtection Systems Corporation.
His notable research included a $1.3 billion joint venture with Roche/Genentech to develop IDO1 inhibitors. Furthermore, he led the successful bench-to-bedside translation of the first FDA-approved Ebola vaccine in partnership with MERCK.
Dr. Link has authored over 120 scientific articles and secured more than $100 million in research funding from institutions like the DOD, NIH and NCI. He has received numerous awards for his translational cancer research endeavours and sits on multiple corporate boards.